Taro Pharmaceutical (NYSE:TARO): Q3 GAAP EPS of $1.46 misses by $0.26.
Revenue of $160.85M (+1.2% Y/Y) misses by $7.71M.
Shares +0.08% AH.
Monday, November 4, 2019
FDA classifies Abbott’s blood pumping system recall as most serious
The U.S. Food and Drug Administration on Monday classified the recall of Abbott Laboratories’ CentriMag blood pumping system following the death of a patient, as Class 1 or the most serious type of recall.
The CentriMag System pumps blood through a patient for up to six hours during open heart procedures and is also used to provide temporary blood circulatory support to patients for up to 30 days.
The system includes a console that controls the pump speed and flow. Abbott initiated the recall due to an error resulting from electromagnetic interference that could cause the pump to slow or stop, according to the FDA.
Slowing of the pump could put patients at the risk of stroke, severe organ damage or death.
Forty-four injuries and one death were reported at the time when Abbott started the recall in August this year, the FDA said on Monday.
The FDA uses the term “recall” when a manufacturer takes corrective action or removes a problematic medical device from the market. A recall does not always mean that customers must stop using the product or return it to the company.
Abbott, which had issued a letter to customers in August with instructions for the continued use of the devices, did not immediately respond to a Reuters request for comment.
Revance Therapeutics EPS beats by $0.02, misses on revenue
Revance Therapeutics (NASDAQ:RVNC): Q3 GAAP EPS of -$0.96 beats by $0.02.
Revenue of $0.05M (-97.9% Y/Y) misses by $0.37M.
Cash and equivalents of $58.92M
Brookdale Senior Living EPS misses by $0.17, revenue in-line
Brookdale Senior Living (NYSE:BKD): Q3 GAAP EPS of -$0.42 misses by $0.17.
Revenue of $1B (-10.7% Y/Y) in-line.
Tenet up 9% after hours on Q3 beat
Tenet Healthcare (NYSE:THC) Q3 results:
Revenues: $4,568M (+1.8%).
Net loss: ($232M) (-999%); loss/share: ($2.24) (-999%). Amount of net loss driven by debt refinancing transaction.
Cash flow ops (9 mo.): $713M (-10.8%).
Q4 guidance: Revenue: $4.678B – 4.878B; net income: $15M – 110M; non-GAAP EBITDA: $749M – 849M; EPS: $0.14 – 1.04; non-GAAP EPS: $0.57 – 1.23.
2019 guidance: Revenue: $18.350B – 18.550B; net loss: ($230M – 135M); loss/share: ($2.23 – 1.31); non-GAAP EPS: $2.25 – 2.91; cash flow ops: $1.045B – 1.325B.
Previously: Tenet Healthcare EPS beats by $0.26, beats on revenue (Nov. 4)
Steris EPS beats by $0.07, beats on revenue
Revenue of $736.8M (+8.5% Y/Y) beats by $19.01M.
Shares -0.08%.
Neurocrine Biosciences EPS misses by $0.09, beats on revenue
Neurocrine Biosciences (NASDAQ:NBIX): Q3 GAAP EPS of $0.56 misses by $0.09.
Revenue of $222.09M (+46.4% Y/Y) beats by $10.78M.
Subscribe to:
Comments (Atom)